INTRODUCTION
Mycobacteria are responsible for considerable human morbidity and mortality worldwide (15, 146, 148) . In the United States, bacteria of this genus have significantly increased in importance in the past decade, largely as a consequence of resurgent infections caused by Mycobacterium tuberculosis and the emergence of M. avium complex (MAC) disease in patients with AIDS. Tuberculosis has affected humans for at least several millenia (3, 29, 135, 165) . It is believed that about onethird of the world's population is infected by M. tuberculosis and therefore is at risk of contracting disease (15, 108 ). An estimated 3 million people globally die of tuberculosis each year, and another 8 million new individuals become infected (15, 86) . Although once thought possible to be virtually eradicated by the end of the century (22) , tuberculosis in the United States has resurged sharply since the mid-1980s, and an estimated 64,000 excess cases have occurred through 1993 (22) (23) (24) (25) .
Members of the MAC are also important causes of disseminated disease and death in AIDS patients (10, 66, 71, 82, 114, 163) . For example, in the United States, 25 to 50% of adults and approximately 10% of children with AIDS are infected with MAC organisms (71, 114) . Adult AIDS patients infected with these bacteria have significantly decreased survival rates compared with individuals without MAC infection (82, 114) .
A steady increase in the frequency of M. tuberculosis strains resistant to one or more agents commonly used in treatment also has been reported (14, 147) . About 13% of new cases are now resistant to at least one first-line or primary antituberculosis drug (isoniazid [INH] , rifampin [RIF] , streptomycin [STR] , ethambutol [EMB] , and pyrazinamide [PZA]), and 3.2% are resistant to both INH and RIF (14) . Several outbreaks of multidrug-resistant M. tuberculosis with devastating consequences for individuals infected with human immunodeficiency virus have occurred in communities such as New York City (23, 39, 43, 46, 137, 138) . It has been well documented that drug-resistant tuberculosis cases are costly to society (94) .
Largely as a consequence of the recent bloom of multidrugresistant tuberculosis in several communities, and the relatively restricted number of efficacious therapeutic agents available to treat patients infected with MAC organisms, there has been renewed effort to define the molecular genetic basis (that is, at the nucleotide or gene level) of antimicrobial resistance in mycobacteria. One of the assumptions underlying much of this research is that elucidation of the genetic basis of resistance will lead to formulation of rapid and unambiguous strategies for detection of resistant strains, which is currently a slow process (67, 176) . It is also thought that knowledge gained from a molecular genetic understanding of resistance mechanisms can be exploited in efforts directed toward rational design of new antimicrobial agents. Progress has been made, largely with M. tuberculosis. Inasmuch as most of the significant advances have been made from studies of M. tuberculosis and M. leprae, rather than MAC organisms, this review will be heavily weighted toward the first two species. In addition, molecular genetic techniques designed to shorten the time required to generate initial antimicrobial susceptibility data will be summarized. This review is specifically designed to cover recent molecular genetic information. Readers interested in other topics in mycobacterial antimicrobial agent research are referred to excellent recent reviews (70) (71) (72) .
RIFAMPIN

Background
RIF was introduced for use in antitubercular therapy in the early 1970s and is a very important component of current treatment regimens. On the basis of detailed structure-function studies conducted with Escherichia coli, the molecular mechanism of RIF activity involves inhibition of DNA-dependent RNA polymerase (48, 173) . In E. coli, this enzyme is a complex oligomer composed of four different subunits (␣, ␤, ␤Ј, and encoded by rpoA, rpoB, rpoC, and rpoD, respectively), which can occur either as a core enzyme (␣ 2 ␤␤Ј) or a holoenzyme (␣ 2 ␤␤Ј plus ). RIF binds to the ␤ subunit of E. coli RNA polymerase and results in transcription inhibition (97) . Recent evidence (91) indicates that the mechanism of action in M. smegmatis is similar to that in E. coli.
Genetic studies conducted in the early 1980s recorded that E. coli strains resistant to RIF had missense mutations and short deletions in the rpoB gene (92, 120, 121) . In addition, Jin and Gross (74) later described 17 mutational alterations affecting 14 amino acid residues in the E. coli RNA polymerase ␤ subunit that mediate RIF resistance in this organism. These E. coli studies formed the basis for molecular genetic studies (63) examining the role of mycobacterial rpoB mutations in strains found to be RIF resistant by in vitro testing.
M. tuberculosis: Mutations in the Gene (rpoB) Encoding the RNA Polymerase ␤ Subunit
Because resistance to RIF in many E. coli strains was known to arise as a result of missense and other mutations occurring in a discrete region of the rpoB gene (74, 120, 121) , Telenti et al. (158) cloned and sequenced the cognate region of the M. tuberculosis gene by using sequence information available from the M. leprae rpoB gene (62) . The data were used to formulate oligonucleotide primers for amplification and sequencing of a 411-bp fragment of rpoB from 66 RIF-resistant and 56 RIFsusceptible strains recovered from patients from several continents. A total of 15 distinct mutations involving eight conserved amino acids clustered in a 23-amino-acid region (69 bp) were identified in 64 of 66 RIF-resistant strains but in none of 56 susceptible organisms. Virtually all of the mutations were missense mutations, and amino acid substitutions at one of two positions (residues 526 and 531) were found in 80% of the resistant strains. Interestingly, no synonymous (silent) nucleotide substitutions were identified in the 122 isolates sequenced for the 411-bp region. For resistant strains bearing many of these rpoB mutations, MICs in excess of 8.0 g of RIF per ml have recently been reported (16) .
Although organisms from nine countries were studied by Telenti et al. (158) , only 12 U.S. isolates were examined. As a consequence, Kapur et al. (78) used automated DNA sequencing to characterize a collection of 128 isolates from this country, including 121 RIF-resistant organisms, for polymorphism in a 350-bp region of rpoB containing the 69-bp stretch with mutations associated with RIF resistance. Twenty-three distinct rpoB alleles were identified. The data confirmed that greater than 90% of RIF-resistant strains have sequence alterations in the 69-bp region and showed that the great majority of the changes are missense mutations. The analysis also identified several mutant rpoB alleles not previously associated with resistant organisms and one short region of rpoB that had an unusually high frequency of insertions and deletions. Twelve of the mutant rpoB alleles were created by point mutations affecting seven amino acids, two were due to insertions of 3 or 6 bp, three were made by deletion of 6 bp (two alleles) or 9 bp (one allele), and six were characterized by combinations of two point mutations.
One unexpected and important finding of this study was a difference in the relative abundance of certain mutations compared with that reported by Telenti et al. (158) . For example, strains with a CAC3TAC codon 526 change (His3Tyr) accounted for about 30% of the U.S. collection examined by Kapur et al. (78) , whereas organisms with this mutation represented only 12% of the sample studied by Telenti et al. (158) . Similarly, only about 25% of strains in the former study had a TCG3TTG (Ser3Leu) mutation in codon 531, whereas organisms with this change accounted for 47% of the strains in the latter study sample. In the absence of sampling bias, the data are most readily explained by geographic variation in the frequency of occurrence of particular rpoB mutations.
A subsequent study of 77 additional strains drawn largely from U.S. patients by Kapur et al. (77) extended knowledge about the spectrum of rpoB mutations associated with RIF resistance. Most resistant organisms had one of the previously described rpoB mutations, and five new mutations were identified. Interestingly, two of the previously undescribed mutations occurred outside the 69-bp core region containing nucleotide changes in virtually all RIF-resistant M. tuberculosis isolates, therefore expanding the size of the core region to 27 amino acids (81 bp) (Fig. 1) detected mutations had not been previously described (77, 78, 158) . No mutations were found in 27 RIF-susceptible strains examined. RIF-resistant strains of M. tuberculosis recovered from patients living throughout the world have also been analyzed by Williams et al. (170) . Resistance to this antimicrobial agent was determined by the proportion plate method (1 g of RIF per ml) (166) , and isolates with greater than 1% growth on RIFcontaining media compared with growth on control media (no antimicrobial agent) were considered resistant. These investigators examined the DNA sequences obtained from a 305-bp fragment of rpoB from 110 RIF-resistant and 10 RIF-susceptible organisms and found missense mutations in the 81-bp target region coding for amino acids 507 through 533 in 100 (91%) of the strains. In addition, one strain each had an insertion and deletion of one amino acid in this region. As described by other investigators (58, 77, 78, 158) , most amino acid substitutions affected His-526 or Ser-531. A summary of rpoB mutations associated with RIF resistance is presented in Fig. 1 and Table 1 . In total, 315 of 329 (96%) RIF-resistant strains have been found to harbor rpoB mutations, and 35 distinct allelic variants have been described. The mechanism of resistance in the 14 (4%) strains lacking mutations in the 81-bp rpoB core region remains unknown. In this regard, it is noteworthy that sequence analysis of rpoB from eight RIF-resistant strains without rpoB core region mutations failed to identify mutations in other regions of the gene (157) , including those with amino acid changes associated with RIF-resistant E. coli (92) . This result implies that at least one additional molecular mechanism mediates RIF resistance in M. tuberculosis. Potential mechanisms include alterations in RIF permeability and mutations in other RNA polymerase subunits.
Recent analysis of 29 RIF-resistant organisms recovered from patients in South Korea, Brazil, and Mexico identified missense mutations in rpoB in 28 of the strains (106) . The bacteria were judged to be resistant on the basis of either the standard proportion or MIC method (164) . As described by other investigators, resistance in most strains was associated with amino acid substitutions located at position 516, 526, or 531 (106) .
In an effort to directly determine the role of rpoB mutations in conferring RIF resistance in mycobacteria, Miller et 
Other Mycobacteria: rpoB Mutations
RIF also is a critical component of M. leprae chemotherapy and has been used previously in combination with other drugs to treat MAC organisms (82) . A related antimicrobial agent, rifabutin, has been widely used in AIDS patients. The in vitro RIF susceptibility varies significantly among MAC serovars. Most MAC organisms are resistant in vitro, and RIF MICs for them exceed 100 g/ml (70) (71) (72) .
Resistant mutants are known to arise in leprosy patients receiving RIF monotherapy. The elucidation of the sequence of the M. leprae rpoB gene (62) permitted identification of mutations associated with RIF resistance in strains taken from nine patients with lepromatous leprosy (63) . Missense mutations affecting Ser-425 (analogous to Ser-531 in M. tuberculosis) were identified in eight of the samples, and in the ninth sample, a 6-bp insertion was found in the same area of rpoB that contains an unusually high frequency of insertions and deletions in M. tuberculosis. Interestingly, no changes were found in the codon corresponding to position 526 (His) that is commonly mutated in RIF-resistant M. tuberculosis.
Strains of RIF-resistant M. leprae (n ϭ 4), M. africanum (n ϭ 2), and M. avium (n ϭ 4) have recently been characterized by Williams et al. (170) for mutations in the 81-bp region of rpoB containing sequence changes in most RIF-resistant M. tuberculosis organisms. For these studies, the M. leprae strains were tested for RIF susceptibility by a mouse footpad assay (139) , M. africanum susceptibility testing was conducted by the proportion plate method (1 g of RIF per ml) (164) , and the susceptibility of M. avium strains to RIF was assayed by the proportion method with 40 g of RIF per ml incorporated into Lowenstein-Jensen slants (170) . The four M. leprae strains each had a Ser3Leu substitution at amino acid residue 425. One strain of M. africanum had the same change, but the second isolate had a wild-type sequence in the 305-bp rpoB region studied. For the M. avium organisms, one strain had a Ser3Trp alteration in the homolog of amino acid 531, one had a Ser3Leu change at this position, and the other two had wild-type sequences in the rpoB region characterized. It is a curious circumstance that no substitutions occurred at His-526, or its homolog, among non-M. tuberculosis (strict sense) isolates, an observation that warrants explanation at the molecular level. A total of 31 MAC isolates with variable levels of RIF susceptibility were examined for sequence variation in the region of rpoB with RIF resistance-associated mutations in M. tuberculosis and M. leprae (50) . Only one of the 31 organisms contained a missense mutation in the target region, a result that was interpreted to mean that alternative mechanisms are responsible for the intrinsic RIF resistance in MAC organisms. Although it is a formal possibility that missense or other mutations elsewhere in rpoB mediate resistance, the description (68) of a significant permeability barrier to RIF in one M. intracellulare strain suggests that restricted drug access to the target molecule is the main process mediating intrinsic RIF resistance. Additional potential mechanisms, including modifications of drug uptake or efflux and the occurrence of a RIF-inactivating enzyme, have not yet been probed in detail.
RIFABUTIN
M. tuberculosis rpoB Mutations
Rifabutin is a spiro-piperidyl derivative of rifamycin S that has potent antimycobacterial activity (35, 116, 136) . In recent years, rifabutin has been commonly used in the prophylaxis against MAC infections in AIDS patients (114, 163) .
The observations that some RIF-resistant strains of M. tuberculosis remain susceptible to rifabutin (32, 33) and patients with RIF-resistant pulmonary tuberculosis may improve when treated with this drug (49, 61, 126) suggested that rpoB mutation position and type of amino acid change influence rifabutin susceptibility. This idea was recently tested by Bodmer et al. (16) , who performed quantitative susceptibility testing with RIF, rifabutin, and rifapentine on 36 RIF-resistant strains with 14 distinct rpoB mutations. MICs were determined by the BACTEC 460 radiometric method (142) , and the following MICs were obtained for wild-type organisms: RIF, 0.25 to 0.5 g/ml; and rifabutin and rifapentine, Ͻ0.015 to 0.125 g/ ml.
A clear correlation between the level of resistance to these drugs and specific mutations in rpoB was discovered. All organisms with 9 of the 14 mutant rpoB alleles (Gln-5133Leu; His-5263Arg, Asp, Pro, Tyr, or Gln; and Ser-5313Leu, Trp, or Tyr) had high-level cross-resistance to rifabutin and rifapentine (MICs, Ͼ4.0 g/ml). In striking contrast, for strains with Leu-5113Pro, Asp-5163Tyr, Asp-5163Val, or Ser5223Leu changes, rifabutin MICs were Յ0.5 g/ml, and therefore the strains were categorized as moderately susceptible or low-level resistant (52) . For rifapentine, all organisms were high-level cross-resistant to RIF except one with an Asp5163Tyr amino acid substitution (MIC ϭ 0.5 g/ml). Although there is only limited clinical experience in treating RIF-resistant M. tuberculosis with rifabutin (49, 61, 126) , these data suggest that patients with strains containing certain rpoB mutations may be amenable to rifabutin therapy. There remains a need for molecular genetic studies to directly probe the exact relationship between rpoB mutations and resistance to rifabutin, rifapentine, and other new rifamycin derivatives (177, 178) .
STREPTOMYCIN Background
STR is an aminocyclitol glycoside antibiotic that is widely used in tuberculosis therapy. The exact mechanism of action of STR has not been extensively investigated in mycobacteria, but in E. coli the antibiotic binds to 16S rRNA, interferes with a proofreading step in translation, and inhibits translational initiation, thereby perturbing protein synthesis (48, 105, 115) . Expression of aminoglycoside-modifying enzymes is the most common mechanism of aminoglycoside-aminocyclitol resistance in bacteria, and these enzymes are generally encoded by resistance plasmids. However, clinically significant aminoglycoside-modifying enzymes have not yet been described in mycobacteria.
Although most eubacteria have multiple copies of rRNA operons, slowly growing mycobacteria such as M. tuberculosis and M. leprae have only one copy, and M. smegmatis, a rapidly growing species, has only two copies (11, 152) . The practical implication of the observation of one 16S rRNA gene copy in the slowly growing mycobacteria is that single nucleotide changes can result in antibiotic resistance (dominant behavior), whereas in E. coli, a bacterium with seven 16S rRNA gene copies, or M. smegmatis, with two copies, nucleotide changes in a single rRNA gene are not expected to confer resistance (recessive behavior).
M. tuberculosis: Mutations in Genes Encoding 16S rRNA (rrs) and Ribosomal Protein S12 (rpsL)
Mutations associated with STR resistance in M. tuberculosis have been identified in two targets, the 16S rRNA gene (rrs) (Fig. 2 ) and the gene (rpsL) encoding ribosomal protein S12 ( Fig. 3 and Table 2 ). In E. coli, the ribosomal protein S12 closely interacts with and stabilizes a highly conserved pseudoknot structure formed by 16S rRNA (105, 115) . Amino acid replacements in protein S12 affect the higher-order structure of 16S rRNA (1) and confer STR resistance to E. coli (47) . In addition, alterations in 16S rRNA disrupt interactions between 16S rRNA and paromomycin, a compound related to STR (34) . The function of the mycobacterial S12 protein is presumed to be cognate with that identified in E. coli, but this has not been formally demonstrated.
Douglass and Steyn achieved the first insight into the molecular basis of STR resistance in M. tuberculosis (36) . These investigators used PCR, DNA sequencing, and the amplification refractory mutation system method (113) to identify an A3G mutation at position 866 in the 16S rRNA gene of 2 of 11 STR-resistant patient isolates from South Africa. (To maximize clarity, note that position 866 is identical to position 904 described in work summarized below.) Neither the method of susceptibility testing used nor the level of resistance to STR was stated. Position 866 in M. tuberculosis 16S rRNA is thought to be functionally analogous to position 913 in E. coli 16S rRNA. Studies with the latter organism had provided evidence that mutations in the position 915 region of E. coli 16S rRNA reduced binding of STR to the ribosome and thereby protected against antibiotic inhibition of ribosome function in vitro (89, 105) . The occurrence of the A3G substitution in STR-resistant organisms, its absence in published mycobacterial 16S rRNA sequences from susceptible organisms, and the data from E. coli studies together were interpreted as evidence of a role for the mutation in mediating resistance. covered from patients were then examined for sequence polymorphism in rrs and rpsL. Susceptibility testing was conducted by the proportion method (72, 131) , and resistance was defined as growth in Ն6.0 g of STR per ml. All 35 STR-susceptible organisms had identical wild-type sequences for rrs and rpsL.
In contrast, 29 of 38 STR-resistant strains had mutations in rrs (n ϭ 9) or rpsL (n ϭ 20), and all 29 of these isolates had only a single variant nucleotide in these two genes. Among organisms with alterations in 16S rRNA, five were characterized by an A3C transversion at position 513, one had an A3T transversion at position 513, and three had C3T transitions at position 516 (Fig. 2) . The 20 strains with rpsL gene mutations had variant codons for amino acids 43 (n ϭ 14) and 88 (n ϭ 6). All mutations observed in the rpsL gene resulted in either Lys3Arg or Lys3Thr substitutions. The molecular basis of STR resistance in M. tuberculosis was also examined by Nair et al. (112) , who independently identified mutations in rpsL associated with resistant organisms. The method used to conduct susceptibility testing was not defined, nor were the MICs of STR given. These investigators studied four pairs of resistant M. tuberculosis strains recovered sequentially from patients treated with STR and found that all organisms had undergone a transition mutation at bp 134 that results in an Arg3Lys (AAG3AGG) substitution at amino acid 43, as noted above. The same mutation was identified in a multidrug-resistant organism and a multidrug-resistant derivative of H37 generated by in vitro passage.
More recently, Meier et al. (98) studied the molecular basis of STR resistance in three M. tuberculosis patient strains. These organisms were resistant to Ն6.0 g of STR per ml on the basis of testing by the proportion method and radiometric proportion technique (72) . One organism had a point mutation (C3T) located at position 491 of the 16S rRNA gene, and the second strain had a C3T mutation at position 512 of this gene. Interestingly, a third strain that was resistant to Ͼ60 g of STR per ml had a mutation at 16S rRNA gene position 904 (A3G) and also a missense mutation in codon 88 of rpsL (AAG3 CAG, Lys3Gln).
Honore and Cole (64) analyzed six STR-resistant and three STR-susceptible patient isolates of M. tuberculosis for the presence of mutations in the rpsL gene. Drug susceptibility testing was performed by the agar dilution method, and organisms capable of growth at Ն4 g/ml were defined as resistant. Two of the six resistant organisms contained a Lys3Arg (AAG3 VOL. 8, 1995 ANTIMICROBIAL AGENT RESISTANCE IN MYCOBACTERIA 501 AGG) substitution in amino acid 43, and none of the three susceptible bacteria had mutations. In addition, two other STR-resistant organisms had mutations at position 903 of rrs. One of these strains had a C3G change and the other organism had a C3A mutation. Twenty-five STR-resistant M. tuberculosis strains recovered from patients in several countries were analyzed for rpsL mutations by SSCP and DNA sequencing by Heym et al. (58) . Susceptibility testing was performed by the agar dilution method, and organisms capable of growth at Ն4 g/ml were defined as resistant. Thirteen of 25 strains (52%) had the same amino acid substitution (Lys3Arg) at position 43 (incorrectly designated as position 42 in reference 58), but none of 16 STR-susceptible organisms had this alteration. Similarly, no other rpsL changes were detected in this sample of strains by SSCP analysis. Among the 12 STR-resistant strains without rpsL mutations, two organisms had nucleotide substitutions in the 16S rRNA gene, but the other 10 strains had no detectable changes by SSCP analysis. Both of the 16S rRNA gene mutations were located at position 903 (designated position 904 in reference 58); one was a C3G change and the other was a C3A substitution. These two organisms are presumably the same strains described in the work cited above (64) . Hence, among 25 STR-resistant M. tuberculosis strains, 15 (60%) had identifiable mutations in two genes associated with antimicrobial resistance. a GenBank numbers: rpoB (LO5910, L27989); inhA (UO2492); gyrA (L27512); rpsL (X70995); rrs (X52917); katG (X68081). Note that for the rpoB gene, accession number LO5910 contains a fragment of the gene described in reference 158, whereas the entire gene is deposited under accession number L27989 (103) .
b The inferred protein encoded by inhA shares 40% amino acid identity over 203 amino acids with the EnvM proteins (12, 162) of Salmonella typhimurium and E. coli (5) .
c Orf1 has significant sequence similarity to several proteins participating in fatty acid biosynthesis (5 (109, 110) .
In summary, on the order of two-thirds of the STR-resistant strains of M. tuberculosis have detectable mutations associated with resistance to this antimicrobial agent. This observation implies that there is at least one additional mechanism conferring STR resistance, and future molecular genetic studies should be targeted to identify the gene(s) involved. In addition, there is a need for unambiguous molecular genetic demonstration that the mutations recorded in STR-resistant M. tuberculosis actually mediate resistance to this antimicrobial agent.
M. smegmatis: Mutations in rpsL
Mutations conferring STR resistance to M. smegmatis in the laboratory have been examined by Kenney and Churchward (83) . (M. smegmatis is frequently used in genetic studies because it grows rapidly, is nonpathogenic, and like several other mycobacterial species, is transformable in the laboratory by electroporation.) Twenty-eight independent spontaneous mutants resistant to STR (Ն20 g/ml) were characterized for mutations in rpsL and rpsG, encoding ribosomal proteins S12 and S7, respectively. Twenty-five of the 28 strains were resistant to Ͼ1 mg of STR per ml. Complementation analysis was used to prove that the observed mutations were responsible for STR resistance. To determine the identity of the mutations conferring resistance, chromosomal DNA was isolated from the 28 strains and the rpsL gene was amplified by PCR and sequenced. All mutations were missense point mutations and occurred in codon 43 or a short region containing codons 86, 88, and 91. Twenty-four of 28 (86%) of the mutations affected Lys-43 (n ϭ 16 isolates) or Lys-88 (n ϭ 8 isolates), and 13 of the combined 24 identified mutations resulted in substitution of Arg for Lys. Most of the amino acid changes in the Mycobacterium S12 protein have been recorded in E. coli mutants resistant to STR, and many have been identified in naturally occurring STR-resistant strains of M. tuberculosis (41, 98) . Interestingly, all of the STR-resistant M. smegmatis strains had mutations in rpsL, and none had changes in the gene encoding the 16S rRNA subunit, unlike the situation for resistant M. tuberculosis. This observation was attributed to the presence of two copies of the 16S rRNA gene in M. smegmatis but to only a single copy in the slow-growing mycobacteria.
ISONIAZID Background
Although INH (isonicotinic acid hydrazide) was first synthesized in the early part of this century, it was not introduced as an antituberculosis medication until the 1950s. INH and RIF together form the backbone of M. tuberculosis chemotherapy globally. The INH MIC for susceptible M. tuberculosis strains is usually less than 0.02 to 0.05 g/ml, and other members of the M. tuberculosis complex are also highly susceptible to this agent. In contrast, INH is inactive in vitro against most MAC isolates (70) and has a restricted role in therapy of infections caused by other mycobacterial species.
INH has been used widely in M. tuberculosis treatment for over 40 years, but neither the bacterial target nor the mode of action is well understood. Potential insight into the mechanism of INH resistance occurred in 1954 when Middlebrook and colleagues discovered that INH-resistant organisms had decreased catalase activity (28, 100, 102) . This observation was extended by Hedgecock and Faucher (51) , who studied INHresistant organisms and noted an inverse correlation between INH MIC and catalase-peroxidase activity. Although the exact metabolic pathway by which INH exerts its effect is unknown, one working hypothesis postulates that INH or an INH metabolite blocks the synthesis of mycolic acids in drug-susceptible organisms (155, 173, 174) . Evidence that the toxicity of INH against M. tuberculosis is potentiated by the peroxidase activity of the mycobacterial catalase-peroxidase has also been presented (140, 141) .
M. tuberculosis: Mutations in katG Encoding
Catalase-Peroxidase
Primary resistance of M. tuberculosis to INH arises in the laboratory at an estimated frequency of 10 Ϫ5 to 10 Ϫ7 (31), which is several orders of magnitude greater than that reported for RIF (181) . In an effort to elucidate the molecular mechanism responsible for the observed decreased catalase activity associated with INH-resistant organisms, Zhang et al. (179), a result confirming that the protein product of katG (KatG) participated in INH action. In addition, it was observed that in two of three high-level (MIC, Ͼ50 g/ml) resistant patient isolates katG was deleted from the chromosome (180) . These investigators concluded that resistance in a subset of M. tuberculosis strains is due to loss of the complete katG gene. However, they also observed by Southern analysis that most INH-resistant strains had an apparently intact katG gene, although the levels of catalase-peroxidase activity recorded for these organisms were greatly decreased. In addition, Stoeckle et al. 16 strains that were resistant to both INH and ethionamide (ETH). For these organisms, the MICs of INH ranged from 0.2 to Ͼ10 g/ml, and the ETH MICs were equal to or greater than 10 g/ml. These investigators found that 23 of 36 (64%) organisms had mutations in katG, as defined by SSCP analysis. In addition, 5 of the 23 INH-resistant organisms also had SSCP-associated variation in the inhA locus (see next section), and five strains had only inhA locus alterations. Characterization of katG sequences in 18 INH-resistant organisms with altered SSCP patterns found several types of mutations located predominantly in the region encoding the amino-terminal one-half of the protein (57) . The most common mutation (n ϭ 7 strains) was a CGG3CTG change resulting in an Arg3Leu substitution at amino acid position 463. Four additional missense mutations were identified, including GTG3GCG (f-Met3Ala, position 1) in one strain, GAC3 GCC (Thr-275Pro) in one strain, AGC3ACC (Ser-315Thr) in five strains, and CTG3ATG (Leu-587Met) in one strain. Two strains that had a deletion of 12 bp resulting in absence of amino acids 120 to 123 were identified, and one strain had an insertion of 3 bp (CAT, Ile) between codons 125 and 126.
The availability of crystal structures for related enzymes, including yeast cytochrome c peroxidase (42), permitted several inferences to be made about structure-function activities of the katG gene product. The deletion of residues 120 to 123 and the insertion of Ile between amino acids 125 and 126 were predicted to result in diminution of catalase activity, and it was shown that organisms bearing these mutations had only approximately 10% residual catalase-specific activity relative to strains with wild-type katG alleles. The amino acid replacements at positions 275 (Thr3Pro) and 315 (Ser3Thr) were also predicted to result in decreased catalase activity because amino acid residues located close to the equivalent positions in yeast cytochrome c peroxidase and E. coli hydroperoxidase are functionally important (93, 124, 144) . These predictions were borne out by enzymatic studies demonstrating that M. tuberculosis strains with the position 275 or 315 substitutions have virtually no detectable catalase activity (58) . In contrast to the diminished catalase activity observed among organisms with the mutations described above, strains with the Arg-4633Leu substitution had essentially wild-type levels of enzyme activity.
Cockerill et al. (27) have also characterized the katG gene in 15 strains of M. tuberculosis for which INH MICs ranged from Ͻ0.12 to Ͼ32 g/ml, including nine resistant and six susceptible strains. Sequencing of katG from all organisms found that six of nine INH-resistant strains had one or more missense mutations, one strain had a nonsense mutation, one had an 8-bp deletion, and one had no mutations in the coding sequence. In striking contrast to the data presented by Heym et al. (58) , in which virtually all strains had single amino acid substitutions, nine of the strains had multiple missense mutations, including one organism reported to have nine amino acid substitutions. Five of six INH-resistant strains with missense mutations had, in addition to other changes, a G3T transversion in codon 463, resulting in the substitution of Leu for Arg. The six INH-susceptible strains had none to 11 amino acid substitutions compared with a consensus sequence formulated from the data available for all 15 organisms; however, none of the mutations affected Arg-463. The G3T change in codon 463 results in loss of a restriction enzyme site recognized by NciI and MspI and thereby generates a convenient strategy to rapidly screen large collections of organisms for this polymorphism. Analysis of 32 INH-susceptible and 43 INH-resistant strains demonstrated that 19 of 43 (44%) of resistant strains, but only 1 of 32 (3%) of INH-susceptible strains, had lost this restriction site and were presumed to contain the G3T mutation resulting in an Arg3Leu substitution.
On the basis of these data, two divergent views regarding the level of katG allelic variation in natural isolates of susceptible and resistant M. tuberculosis and the characteristics of katG variants associated with INH resistance emerged. To provide additional data bearing on the issue of katG allelic variation in INH-susceptible and -resistant organisms, Musser et al. (111) sequenced katG and the inhA locus in entirety from 34 resistant and 12 susceptible strains from global sources. Virtually all resistant organisms had amino acid changes in KatG or nucleotide substitutions in a presumed upstream regulatory region of inhA. Moreover, sequence analysis of a region of katG encoding residues Ser-315 and Arg-463, and the inhA locus, in 10 susceptible and 51 INH-resistant organisms from The Netherlands found that 84% of resistant bacteria had mutations in katG or the inhA locus. Interestingly, all 16 strains of M. bovis and M. microti had Leu-463 rather than Arg-463 in katG, a result consistent with the hypothesis that Leu-463 is the ancestral condition in M. tuberculosis. Taken together, the data are consistent with results showing that very little katG allelic variation occurs in INH-susceptible strains, and a restricted subset of missense changes are repeatedly associated with INH resistance.
To summarize, missense and other mutations in katG that are associated with resistance to INH have been identified (Fig. 4) . Although there is evidence to suggest that one or more of the variant katG alleles confers INH resistance, there is clearly a need for additional molecular genetic data addressing the exact role of some of the nonsynonymous substitutions described by several investigators.
M. tuberculosis: inhA Locus Polymorphisms
The observations that only a relatively modest percentage of INH-resistant M. tuberculosis strains are catalase negative and have gross alterations (149) or missense or other mutations involving katG (27, 57) indicated that other molecular mechanisms mediating INH resistance remained to be discovered. As a consequence, there has been a concerted effort by several groups to isolate additional genes involved in INH resistance. Banerjee et al. (5) identified a locus containing two contiguous open reading frames (designated orf1 and inhA) coding for products that may participate in resistance to both INH and ETH (Fig. 5) . ETH is a structural analog of INH that is sometimes used as a second-line antituberculosis drug. ETH, like INH, is thought to inhibit mycolic acid biosynthesis in M. tuberculosis and other mycobacteria (173, 175) . In addition, studies (21, 60, 90) have demonstrated that for certain strains low-level INH resistance correlated with coacquisition of ETH resistance rather than loss of catalase activity. Taken together, these observations suggested that the two antimicrobial agents may share a common target and led to formulation of an elegant molecular genetic strategy to identify the structural gene encoding a putative target. bovis, the two genes are separated by a short noncoding region of 21 bp that lacks a readily identifiable promoter. Hence, orf1 and inhA together may constitute a two-gene operon that is transcribed from a promoter located in front of orf1 (Fig. 5) . The inferred proteins made by inhA of M. tuberculosis (and M. bovis and M. smegmatis) have greater than 40% sequence identity over a stretch of 203 amino acids with the EnvM proteins of E. coli and Salmonella typhimurium. EnvM is thought to participate in fatty acid biosynthesis (12, 162) and has been shown to catalyze the reduction of crotonyl-acyl carrier protein (13) . In this regard, it is noteworthy that a Gly933Ser-93 substitution in EnvM in E. coli resulted in resistance to diazaborine, an inhibitor of fatty acid, phospholipid, and lipopolysaccharide biosynthesis (162) . The predicted protein made by orf1 has greatest identity with 3-ketoacyl-acyl carrier protein reductase coded for by fabG of E. coli, an enzyme thought to be involved in fatty acid biosynthesis (5) . On the basis of the hypothesis that INH and ETH act by inhibiting synthesis of mycolic acid, it is noteworthy that analogs of the predicted proteins made by orf1 and inhA have roles in E. coli fatty acid synthesis. Moreover, cell extracts prepared from the resistant mutant strain, or from resistant merodiploids harboring multiple inhA copies, had significant resistance to INH-mediated inhibition of mycolic acid biosynthesis.
The identification of the missense mutation in inhA conferring mycobacterial resistance to INH and ETH in the laboratory led to the plausible hypothesis that missense mutations in inhA would constitute a very abundant cause of resistance among strains of M. tuberculosis recovered from patients. Surprisingly, this is not the case. The entire inhA gene, including the upstream putative regulatory region, was sequenced by Kapur et al. (77) in a sample of 37 INH-resistant organisms (including some resistant to INH plus ETH) collected from diverse localities in the United States. With only one exception, all strains had the identical wild-type inhA allele, and none contained the Ser-943Ala-94 substitution. The one exceptional strain had a missense mutation (ATC3ACC, Ile163Thr-16) located at nucleotide 47. Variation was then examined in the 744-bp orf1 gene in 24 resistant patient isolates, and surprisingly, polymorphisms were identified at two nucleotides flanking a presumed ribosomal binding site in four of these isolates (77) . Although one strain had a synonymous substitution at nucleotide position 102, no other orf1 mutations were found in resistant organisms or in upstream or coding regions of seven susceptible strains (77) . On the basis of these studies, it is possible that the base-pair substitutions flanking the presumed orf1 ribosomal binding site result in altered regulation of Orf1 and/or InhA in some M. tuberculosis strains (Fig. 5) .
Related data have also been generated recently by Morris et al. (106) , who examined the inhA locus for sequence polymorphisms by a combination of SSCP and DNA sequencing in a sample of 42 INH-resistant isolates. No alterations were identified in the inhA coding region, but five isolates had mutations in the putative regulatory region containing a possible ribosome binding site. Two strains had a T3G transversion, two strains had a C3T transition, and one organism had an A3G tuberculosis. The inhA locus is composed of two contiguous open reading frames (designated orf1 and inhA) coding for protein products that may participate in resistance to INH and perhaps ETH (5). The 28.5-kDa protein product encoded by the 810-bp inhA gene has significant homology with the EnvM protein of E. coli, a molecule thought to participate in fatty acid biosynthesis (11, 162) . The predicted 25.7-kDa protein made by orf1 (744 bp) has significant similarity to 3-ketoacyl-acyl carrier protein reductase encoded by fabG of E. coli, and this enzyme is also thought to be involved in fatty acid biosynthesis (5). In M. tuberculosis and M. bovis, orf1 and inhA are separated by a 21-bp noncoding region that lacks a readily identifiable promoter (5) , and the genes are presumed to constitute a two-gene operon that is transcribed from a promoter located upstream of orf1. Variation has been identified by automated DNA sequencing and other strategies in a putative ribosome binding site area located immediately upstream of orf1 in some M. tuberculosis strains resistant to INH alone or to both INH and ETH (77, 106) . No sequence variation has been identified in this region, or in other nucleotides of the inhA locus, in susceptible organisms (77, 105) . VOL. 8, 1995 ANTIMICROBIAL AGENT RESISTANCE IN MYCOBACTERIA 505 change in nucleotides located in the region upstream from the orf1 structural gene (106) (Fig. 5 ). These observations are consistent with the identification of putative inhA regulatory region mutations in 10 of 36 INH-resistant organisms studied by Heym et al. (58) . It is noteworthy that in the studies by Kapur et al. (77) , Morris et al. (106) , and Heym et al. (58) , mutations in the putative inhA locus regulatory region occur in a disproportionately higher percentage of strains resistant to both INH and ETH than in organisms resistant to INH but susceptible to ETH. This observation suggests a causal relationship between the putative regulatory region nucleotide substitutions and resistance to the two antimicrobial agents. The lack of Ser-943Ala-94 substitutions among the patient isolates clearly provides a sobering reminder of the importance of correlating laboratory observations with molecular study of large samples of patient strains. Recently, additional data about structure and function relationships of the InhA protein have become available (33) . Wild-type InhA catalyzed the reduction of 2-trans-octenoylacyl carrier protein, a result demonstrating that the inhA gene product is an enoyl-acyl carrier protein reductase. This result is consistent with the hypothesis that InhA participates in mycolic acid biosynthesis. Comparison of enzyme kinetic parameters of wild-type InhA with those of the Ser-943Ala-94 InhA variant found no difference in the K m and V max values. However, the Michaelis constant for NADH was five times higher in the Ser-943Ala-94 mutant, a result suggesting that the mechanism of drug resistance is related to specific enzymecofactor interactions in the NADH binding site. Interestingly, the side chain of Ile-16 (an amino acid replaced by Thr-16 in one INH-resistant clinical isolate [78] ) is also located in the NADH-binding cleft and is positioned close to the adenine ribose portion of NADH. Hence, it is very likely that substitution of the hydroxyl side chain of Thr-16 for the alkyl group of Ile-16 perturbs the hydrogen-bonding pattern of the NADHbinding site and leads to significant differences in cofactor interaction.
Despite the availability of these detailed molecular interaction data, many issues about the role of inhA locus mutations in INH resistance remain unresolved. First, thus far, neither INH nor ETH has been shown to bind to InhA, which suggests that activation of these antimicrobial agents may be necessary. Second, it remains unknown if InhA and KatG interact, and if so, how it occurs, and if the mutations identified at the inhA locus and katG result in altered interactions. In this regard, Dessen et al. (33) have hypothesized that the Ser-943Ala-94 and Ile-163Thr-16 substitutions result in a decreased binding affinity of InhA for NADH. The change in kinetics of enzymecofactor interactions then alters subsequent binding of a putative activated form of INH, ultimately resulting in INH resistance. Although no detailed hypothesis has been advanced in light of the new InhA structure-function data to explain the mechanism by which orf1 regulatory region mutations might produce resistance to INH, the upstream mutations may result in increased InhA protein expression.
In summary, the molecular basis of resistance to INH for some M. tuberculosis strains appears to involve mutations in katG and perhaps putative inhA locus regulatory sequences. However, mutations in these genes clearly do not account for all INH-resistant strains. The observation (132, 133 ) that mutations in the E. coli oxyR regulon influence the susceptibility of this organism to INH suggests possible additional mechanisms involved in INH resistance. Moreover, there has been essentially no work done to examine the potential role of INH permeability changes in mediating resistance. Clearly, much additional genetic and biochemical work is needed to elucidate the complex mechanism of resistance to this antimicrobial agent.
FLUOROQUINOLONES Background
The increasing frequency of recovery of multidrug-resistant M. tuberculosis strains resistant to most first-and second-line antituberculosis agents has resulted in substantial use of other antimicrobial agents in patients infected with these problem strains (150) . Fluoroquinolones (FQ), mainly ciprofloxacin (CIP), have been employed, but resistance to these agents develops relatively rapidly (61, 150) . FQ antimicrobial agents are variably active in vitro against MAC organisms and other mycobacterial species. CIP has been employed in combinationtherapy regimens to treat MAC infections (82) .
Study of quinolone activity in many bacterial species has found that the primary target of these antimicrobial agents is DNA gyrase, a type II DNA topoisomerase that is composed of two A and two B subunits, encoded by gyrA and gyrB, respectively (65) . Missense mutations in the putative FQ binding region of the A subunit have been found to confer highlevel resistance in several bacterial species (65) . This region is highly conserved in E. coli, Staphylococcus aureus, and Campylobacter jejuni and is referred to as the quinolone resistance-determining region. Other mutations conferring FQ resistance have been found in the gene (gyrB) for the B subunit, although these mutations tend to confer lower-level resistance (65) .
Ciprofloxacin-Resistant M. tuberculosis: Mutations in gyrA
Encoding the A Subunit of DNA Gyrase
As a first step toward understanding the molecular mechanism of FQ resistance in M. tuberculosis, Takiff et al. (156) cloned and sequenced the wild-type gyrA and gyrB genes encoding the A and B subunits of DNA gyrase, respectively. The gyrA gene (2,517 bp) is located 36 bp downstream of gyrB (2,060 bp), and the inferred M. tuberculosis GyrA and GyrB proteins have 69 and 63% similarity to the E. coli gyrase subunits, respectively. Four CIP-susceptible reference organisms, six CIP-resistant laboratory mutants of the M. tuberculosis complex, 54 patient isolates of M. tuberculosis (39 CIP-susceptible and 15 CIP-resistant organisms), and one CIP-susceptible patient isolate of M. africanum were then screened by PCR-SSCP for gyrA and/or gyrB polymorphisms. With a single exception, MICs for all resistant patient strains were greater than or equal to 4 g/ml. A 320-bp PCR product of gyrA and a 428-bp PCR-generated fragment of gyrB corresponding to regions in genes from E. coli and other bacterial species with CIP-conferring mutations were studied. The 320-bp gyrA fragment was sequenced from all strains in the sample. Two gyrA SSCP patterns were identified among CIP-susceptible organisms and eight gyrA SSCP patterns were found among resistant bacteria; all strains had a single gyrB SSCP pattern. A total of five polymorphic codons (positions 88, 90, 91, 94, and 95) were identified in gyrA by DNA sequencing. Codon 95 contained a naturally occurring polymorphism (AGC, Ser; or ACC, Thr) that may be unrelated to CIP resistance because it occurred in both FQ-susceptible and FQ-resistant organisms. In contrast, the other four polymorphic codons contained changes unique to the CIP-resistant strains, with position 94 being the most highly variable. All patient isolates for which MICs was greater than or equal to 4 g/ml had variant codons not represented among susceptible strains. No simple relationship between dis-tinct variant codons and CIP MICs was observed, although all eight strains for which MICs were Ͼ8 g/ml had mutations in codon 94. Hence, gyrA mutations were identified in all strains for which the CIP MIC was Ͼ2 g/ml, a value that has been proposed as a cutoff for clinical CIP resistance (54) .
On the basis of the observation that CIP-resistant M. tuberculosis strains for which MICs were Ͼ4.0 g/ml contain missense mutations in gyrA, Kapur et al. (77) sequenced a 320-bp region of gyrA in 17 isolates, including a sample of 12 isolates that were resistant to CIP. Virtually all (16 of 17) strains, including both resistant and susceptible organisms, had an AGC3ACC (Ser3Thr) mutation in codon 95 of gyrA that is apparently unrelated to CIP resistance. Among the resistant strains, three organisms had missense mutations in codon 94, and two resistant strains had missense mutations in codon 90. No other mutations were identified in the region of gyrA studied. Taken together, these data show that there may not be a simple one-to-one correlation of missense mutations and CIP resistance in M. tuberculosis and imply that the molecular basis of resistance to this drug is complex and remains to be fully elucidated. Additional well-characterized strain samples will need be to be studied in order to fully understand the relationship of missense mutations to antibiotic resistance. Moreover, there is a need for additional molecular genetic studies probing the role of variant gyrA alleles in mediating CIP resistance.
Ofloxacin: gyrA Mutations in Resistant M. tuberculosis and M. smegmatis
Ofloxacin (OFX) has also been used to treat patients with pulmonary tuberculosis (161). Cambau et al. (20) characterized one strain of OFX-resistant M. tuberculosis recovered from a patient with a long history of multidrug-resistant tuberculosis. This organism was resistant to 32 g of OFX per ml on the basis of results determined by the proportion method (70) . DNA sequence analysis of part of the gyrA gene in the initial susceptible organism and the OFX-resistant derivative strain identified a missense mutation (GAC3CAC, Asp3His) in codon 89 (numbering system used in reference 156).
Revel et al. (129) studied polymorphism occurring in five mutant strains of M. smegmatis selected in the laboratory for which OFX MICs were greater than or equal to 2 g/ml. All organisms had missense mutations in codon 90 (GCG3GTG, Ala3Val) or codon 94 (GAC3GGC, Asp3Gly) of gyrA.
OTHER ANTIMICROBIAL AGENTS USED IN MYCOBACTERIAL THERAPY Ethionamide
As noted above, ETH (2-ethylpyridine-4-carbonic acid thioamide) is a derivative of isonicotinic acid with potent activity against M. tuberculosis and other mycobacteria (38, 60, 90, 130) . Most M. tuberculosis strains are inhibited in vitro by ETH concentrations in the range of 10 to 20 g/ml. On the basis of the observation that cells treated with ETH lose the property of acid fastness, and some experimental data (5, 175) , it is thought that the mechanism of action involves inhibition of mycolic acid biosynthesis. The exact mechanism of ETH resistance is unknown, but some strains resistant to both INH and ETH harbor mutations in a putative regulatory region located upstream of the orf1 gene in the inhA locus (Fig. 5) (5, 58, 77) .
Ethambutol
EMB is a very specific and effective drug that is used in combination with INH to treat M. tuberculosis infection (76, 80, 160, 171) . The molecular mechanism of EMB action is unknown, but experimental data have been generated and several hypotheses have been advanced to explain its action (9, 26, 44, 45, 73, 84, 88, 123, 125, 128, 143, 153, 154) . Most of the data have been generated from study of the effects of EMB on mycobacterial species other than M. tuberculosis. Among the effects attributed to EMB are inhibition of RNA metabolism (44, 45) , phospholipid synthesis (26, 84) , transfer of mycolic acids to cell wall-linked arabinogalactan (153) , spermidine synthesis (123, 125) , and an early step of glucose conversion into the monosaccharides used for the cell wall polysaccharides arabinogalactan, aribinomannan, and peptidoglycan (143) . Thus far, no genes known to encode products participating in EMB resistance have been described.
Pyrazinamide
PZA is a synthetic derivative of nicotinamide that has been used in some short-course antituberculosis treatment regimens. Neither the biochemical mechanism of action nor the molecular basis of resistance is fully known. Several investigators have reported that PZA-susceptible M. tuberculosis strains have a pyrazinamidase that metabolizes PZA to pyrazinoic acid and that PZA-resistant organisms have lost pyrazinamidase activity (19, 87, 96) . Although the exact antimycobacterial moiety is unknown, Heifets et al. (53) have demonstrated that pyrazinoic acid is likely to participate. On the basis of these observations, one can speculate that any molecular mechanism resulting in loss of or decreased PZA activity (e.g., loss of pyrazinamidase structural gene or missense mutations resulting in an altered allele) may lead to PZA resistance. However, that fact that highly PZA-resistant strains do not always lack pyrazinamidase activity (19) suggests that more than a single resistance mechanism may operate.
Capreomycin, Viomycin, and Kanamycin
Capreomycin and viomycin are polypeptide antimicrobial agents that are sometimes used in combination therapy for treatment of drug-resistant M. tuberculosis strains (56) . Kanamycin is an aminoglycoside that is also used to treat resistant organisms. Although strains that acquire resistance to capreomycin generally remain susceptible to other antituberculosis medications, cross-resistance with kanamycin and viomycin can occur (95, 151) . For example, McClatchy et al. (95) reported complete cross-resistance between viomycin and capreomycin among laboratory-generated resistant mutants of M. tuberculosis. However, cross-resistance between kanamycin and capreomycin and between kanamycin and viomycin was variable. In addition, review of the medical histories of 27 patients with kanamycin-resistant M. tuberculosis isolates indicated that cross-resistance with capreomycin and viomycin occurs but, like the in vitro situation, is unpredictable. Currently, no progress has been made in the understanding of the molecular basis of resistance of Mycobacterium spp. to these agents.
Clarithromycin
Clarithromycin is a macrolide antibiotic with substantial in vitro activity against nontuberculosis mycobacteria. Although a clinical trial of clarithromycin monotherapy in AIDS patients demonstrated that within 6 weeks a dramatic decrease occurred in the number of M. avium-M. intracellulare complex VOL. 8, 1995 ANTIMICROBIAL AGENT RESISTANCE IN MYCOBACTERIA 507 bacteria culturable from blood (30) , it has also been observed that drug resistance emerges during monotherapy (134) . Macrolides are bacteriostatic antibiotics that inhibit the peptidyltransferase region of the 50S ribosomal subunit (reviewed in reference 48). Studies of several organisms have found that a peptidyltransferase center located in a small region of 23S rRNA is implicated in macrolide resistance. In E. coli, methylation of an adenine residue in a generally conserved loop of domain V confers resistance to macrolides and several other antibiotics (145) . Because there is increasing interest in using clarithromycin and the related macrolides azithromycin and roxithromycin as therapy for nontuberculous mycobacteria (17, 18, 55) , the mechanism responsible for clarithromycin resistance in M. intracellulare was investigated in six pairs of susceptible and resistant organisms cultured from patients with chronic pulmonary infections undergoing monotherapy with clarithromycin. For the resistant isolates, MICs were Ͼ32 g/ml as assayed by broth microdilution (17, 18) . Three of the six independent clarithromycin-resistant isolates, but none of the susceptible strains, had a single point mutation in domain V of 23S rRNA. One organism each had an A3C, A3G, or A3T change. The position mutated corresponds to E. coli position 2058, which has been implicated in resistance to erythromycin and macrolide-lincomide-streptogramin B antibiotics (99) . The other three resistant organisms had wild-type sequences in the stretch of approximately 400 nucleotides studied. The authors also observed that two M. avium patient isolates with acquired resistance to azithromycin both showed a single point mutation in 23S rRNA (A-20583T and A-20593C). Finally, in a note added in proof, it was stated that two M. avium-M. intracellulare complex strains had an A3C transition at position 2059. Hence, of the total of 10 clarithromycin-resistant M. avium-M. intracellulare isolates studied, 7 (70%) had a mutation of 23S rRNA at position 2058 or 2059.
Tetracycline
Tetracycline and related compounds are sometimes used to treat infections caused by certain rapidly growing nontuberculous mycobacteria. Pang et al. (122) examined a total of seven isolates of tetracycline-resistant M. fortuitum, M. fortuitum third biovariant complex, and M. peregrinum for the presence of sequences homologous to genes encoding resistance to this antimicrobial agent in gram-positive organisms. One isolate each of the M. fortuitum third biovariant complex and M. peregrinum had sequences homologous with genes conferring tetracycline resistance. PCR-based sequence analysis of one of the genes (tetK) found in a strain of the M. fortuitum third biovariant complex revealed 98% identity in the 300-bp region studied. In addition, the sequence had a GϩC content of only 30%, a value that differs significantly from the 70% GϩC typifying mycobacterial genes. Together, the data suggest that these Mycobacterium spp. acquired tetK from a heterologous source, perhaps by conjugation.
MOLECULAR STRATEGIES FOR DETECTION OF MUTANT ALLELES
Several molecular techniques have been formulated to rapidly detect mutations in target genes of interest (6, 40, 113, 118, 119, 127, 167, 168) , including those associated with antimicrobial resistance in Mycobacterium spp. (Table 3 ). These strategies have been used for two main purposes: definition of the frequency distribution of distinct mutations occurring in resistant strains, and rapid indirect identification of resistant organisms. The utility of these strategies is enhanced in M. tuberculosis because with the exception of mutations associated with resistance, there is a striking paucity of nucleotide sequence diversity in many structural genes among isolates recovered from global sources (79) . M. leprae has also been reported to have restricted genetic diversity based on restriction fragment length polymorphism analysis (169) .
The most widely used technique has been DNA sequencing of PCR-amplified targets generated from DNA obtained from mature cultures. Both manual and automated DNA sequencing approaches have been employed. Representative data obtained by automated DNA sequencing of a segment of rpoB in RIF-resistant organisms are shown in Fig. 6 . Other methods applied to identify mutations associated with antimicrobial resistance include simple PCR, PCR-SSCP analysis, the amplification refractory mutation system, PCR-heteroduplex analysis, heminested PCR (167) , and restriction enzyme analysis of PCR products to identify loss or gain of a restriction site ( Table 3) . Several of these strategies, including automated DNA sequencing, PCR-SSCP analysis, and PCR-heteroduplex formation, have been employed to a limited extent to analyze early positive BACTEC 460 cultures and primary patient specimens (77) . Thus far, there have been no published reports of application of a microtiter format point mutation assay that has been successfully applied to detect drug resistance-conferring mutations in human immunodeficiency virus type 1 from patients treated with zidovudine (81) .
One of the promising new strategies for ultrafast, unambiguous, low-cost DNA sequence analysis currently in the developmental stage is termed sequencing by hybridization (4, 7, 8, 37, 85) . This approach exploits the natural base-pairing specificity of multiple DNA probes to ''decode'' the nucleotide sequence of a target DNA molecule. Sequencing by hybridization is also sometimes referred to as matrix hybridization DNA sequencing or simply matrix sequencing. This approach was independently proposed by several groups as a new sequencing strategy about 5 years ago. In sequencing by hybridization, DNA samples are interrogated by hybridization to a complete set of all nucleotide probes of a given length to determine the oligonucleotide content of the DNA sample. As initially described, interrogation would employ a complete set of all oligonucleotide probes of a given length, for example, all 65,536 (4 8 ) octamers. Then, the complete sequence is generated by computer with an algorithm that automatically identifies successive sequence overlaps between oligonucleotide ''words. '' In one of the sequencing by hybridization formats being developed for rapid identification of M. tuberculosis mutations associated with antimicrobial resistance, numerous probes are attached to a surface such as a glass microscope slide. A DNA sample such as a PCR product is then hybridized to the complete set of probes simultaneously. This strategy permits acquisition of the complete sequence information in a single experiment. Both microelectronic and optical detection schemes are being developed to detect hybridization within the oligonucleotide array (7).
VIRULENCE AND DRUG RESISTANCE
One of the very important questions relating to the study of resistant M. tuberculosis is the relative virulence of drug-resistant organisms. This has been a controversial issue for several decades, since it was reported that INH-resistant strains that lack catalase activity have significantly reduced virulence for guinea pigs (101) , and Mitchison et al. (104) reported that a significant number of INH-resistant M. tuberculosis strains isolated from patients in India tended to be of low virulence in a 
CONCLUSIONS
Considerable progress has been made in recent years toward understanding the molecular basis of antimicrobial resistance in mycobacteria. Most work has been conducted with M. tuberculosis, and the primary theme emerging from these studies is that resistance is usually due to simple nucleotide substitutions rather than to acquisition of new genetic elements encoding antibiotic-altering enzymes. Multidrug-resistant isolates of M. tuberculosis arise as a consequence of sequential accu- 
